Pancreatic Carcinoma Non-resectable
7
0
1
2
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
57.1%
4 terminated out of 7 trials
33.3%
-53.2% vs benchmark
14%
1 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
Dose Escalation Study of CyberKnife® SBRT Boost for Patients With Unresectable Locally Advanced Pancreatic Cancer
Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer
Induction Chemotherapy With Gemcitabine and Cisplatin Followed by CCRT for Unresectable Pancreatic Carcinoma
Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer